Can-Fite BioPharma
Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.
Last updated September 11, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The Company has an advanced pipeline of proprietary drug candidates in Phase II and Phase III clinical development which address oncology, inflammatory, and metabolic diseases. Can-Fite's platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. Its drug candidates include Namodenoson (CF102) and Piclidenoson (CF101), and CF602.
Recent events
Can-Fite receives Eurasian patent allowance for Piclidenoson use in Lowe syndrome[5]
Reported:
Can-Fite announced that the Eurasian Patent Office issued a notification of readiness to grant a patent covering Piclidenoson use for diseases associated with OCRL deficiency, including Lowe syndrome and Dent disease 2. The grant remains subject to completion of required formalities.
Can-Fite and Ewopharma sign exclusive distribution agreement[6]
Reported:
Can-Fite announced that it signed an exclusive distribution agreement with Ewopharma. Ewopharma will have exclusive rights to market and sell Piclidenoson in Central Eastern European countries and Namodenoson in Central Eastern European countries and Switzerland, in exchange for upfront and milestone payments and royalties.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/can-fite-biopharma · Editorial policy · How profiles are compiled